ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0619

Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus

OKEOGHENE AKPOIGBE1, BETTINA ESCOLANO2, ENOCH J ABBEY2 and Amanda Sammut3, 1New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, 2New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, 3New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY

Meeting: ACR Convergence 2024

Keywords: Disparities, Miscellaneous Rheumatic and Inflammatory Diseases, Mortality, Outcome measures, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) complicated with hemophagocytic lymphohistiocystosis (HLH) can be life-threatening with mortality as high as 9.9%-10.5%. Estimates of the prevalence of HLH in SLE ranges from 0.9 up to 4.6%, with higher rates reported in racial minority populations, including African American (AA), Hispanic, and Asian American/Pacific Island (AAPI) people, compared to non-Hispanic White people. However, this disparity in prevalence might be decreasing as access to care and availability of treatments for SLE increase in these populations. This study aims to estimate the prevalence and factors predicting HLH in hospitalized patients with SLE.

Methods: A total of 107,590 patients with SLE from the 2018-2020 Nationwide Inpatient Sample database were included in this cross-sectional study. Baseline demographics, including age, sex, and race, were collected along with information on the diagnosis of HLH and mortality. Initial univariate associations between those with and without HLH were assessed using either Student’s t-test for continuous variables or chi-squared tests for categorical variables. Multivariable logistic regression was then used to assess for the association of factors with HLH after accounting for covariates.

Results: Of the 107,590 patients with SLE, 139 had a concurrent diagnosis of HLH for a prevalence of 0.13% [95% CI 0.10 – 0.14%]. An increased risk of HLH was observed in those who were younger, female, or who identified as being AA, Hispanic, AAPI, or Native American. In a multivariable logistic regression model including all potential risk factors of HLH, increasing age was protective while HLH risk remained higher in females. In comparison to White individuals, only those who were AAPI [OR 5.34, 95% CI (3.01 – 9.47)] still had an increased risk for HLH after accounting for covariates. There was a strong association between HLH and mortality [OR 6.39, 95% CI 3.19 – 12.81].

Conclusion: The prevalence of HLH in this study was lower compared to other studies, which may be indicative of either improving care in patients with SLE or underdiagnosis. However, HLH remained associated with high mortality, which could potentially be reduced by earlier assessment and treatment. In this large, recent database, a younger age, being female or of a racial minority continued to be significant factors associated with HLH.

Supporting image 1

Table 1: Baseline Characteristics and Association between HLH and Age, Race, Sex and Mortality

Supporting image 2

Table 2: Prevalence of Hemophagocytic Lymphohistiocystosis (HLH)

Supporting image 3

Table 3: Predicting Factors associated with HLH and Mortality


Disclosures: O. AKPOIGBE: None; B. ESCOLANO: None; E. ABBEY: None; A. Sammut: None.

To cite this abstract in AMA style:

AKPOIGBE O, ESCOLANO B, ABBEY E, Sammut A. Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-factors-predicting-hemophagocytic-lymphohistiocytosis-in-hospitalized-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-factors-predicting-hemophagocytic-lymphohistiocytosis-in-hospitalized-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology